Posted by Michael Wonder on 28 Nov 2018
NICE publishes FAD for new indication for Xeljanz
28 November 2018 - NICE has published a final appraisal document for tofacitinib citrate for the treatment of patients with moderately to severely active ulcerative colitis.
Tofacitinib citrate is recommended, within its marketing authorisation, as an option for treating moderately to severely active ulcerative colitis in adults when conventional therapy or a biological agent cannot be tolerated or the disease has responded inadequately or lost response to treatment.
Tofacitinib citrate is recommended only if Pfizer provides a discount as agreed in the commercial arrangement.
